Clarity Pharmaceuticals Unveils Superior Prostate Cancer Imaging and Therapy Data
Clarity Pharmaceuticals has presented compelling clinical evidence that its investigational 64Cu-SAR-bisPSMA diagnostic and 67Cu-SAR-bisPSMA therapeutic candidates outperform current standards in prostate cancer care, positioning the company for regulatory and commercial milestones.
- 64Cu-SAR-bisPSMA detects more lesions than FDA-approved PSMA PET agents
- Next-day imaging boosts lesion visibility and diagnostic confidence
- 67Cu-SAR-bisPSMA shows promising safety and efficacy in advanced prostate cancer
- Multiple Phase III trials underway to support regulatory approvals
- Australian innovation with proprietary technology targeting large US market
Breakthrough Diagnostic Performance of 64Cu-SAR-bisPSMA
Clarity Pharmaceuticals Ltd (ASX:CU6) has showcased robust clinical data for its lead diagnostic candidate, 64Cu-SAR-bisPSMA, revealing a significant edge over existing FDA-approved PSMA PET agents such as 68Ga-PSMA-11 and 18F-DCFPyL. In head-to-head trials including PROPELLER and Co-PSMA, the copper-64 labelled dimeric agent demonstrated 2-3 times higher tumour uptake and tumour-to-background ratios, alongside a 1.3-fold increase in lesion detection on same-day imaging.
Moreover, next-day imaging with 64Cu-SAR-bisPSMA further amplified lesion visibility by up to 82%, identifying smaller lesions in the 2-millimeter range that standard agents missed. This flexibility in imaging windows, supported by the agent’s longer half-life and extended shelf-life, offers a practical workflow advantage and improved diagnostic confidence in clinical settings.
Clinical Impact and Patient Management Benefits
The enhanced detection capabilities translated into meaningful clinical outcomes. The Co-PSMA Phase II trial reported that 64Cu-SAR-bisPSMA detected 2.6 times more lesions per patient and identified more patients with positive scans compared to 68Ga-PSMA-11. This led to treatment plan changes in 44% of participants, including altered radiation fields and addition of systemic therapies, underscoring the agent’s potential to refine personalised prostate cancer care.
Real-world compassionate use cases corroborated these findings, with 8 out of 10 patients showing lesion detection after negative or equivocal standard-of-care scans, even when using advanced imaging systems like Siemens Biograph Vision Quadra. In all positive cases, 64Cu-SAR-bisPSMA findings prompted clinical management changes.
Therapeutic Promise of 67Cu-SAR-bisPSMA in Advanced Disease
On the therapeutic front, Clarity’s 67Cu-SAR-bisPSMA is advancing through the Phase I/IIa SECuRE trial targeting metastatic castration-resistant prostate cancer (mCRPC). Preliminary results from heavily pre-treated patients show a favourable safety profile, with mostly mild to moderate adverse events and no Grade 4 or higher toxicities reported.
Importantly, high PSA response rates were observed at the 8 GBq dose level, including a 63% PSA50 response rate and 26% achieving PSA90 reductions. Notably, 31% of evaluable participants attained complete response or undetectable disease by combined imaging and PSA assessment. These outcomes highlight the agent’s potential to deliver deep anti-tumour activity in a difficult-to-treat population.
Strategic Positioning and Market Opportunity
Originating from Australian scientific institutions such as the University of Melbourne and the Walter and Eliza Hall Institute, Clarity’s SAR-bisPSMA technology leverages proprietary chelator chemistry and dual PSMA targeting to differentiate itself in a crowded market. The company has secured three FDA Fast Track designations for both diagnostic and therapeutic candidates, reflecting regulatory recognition of unmet medical need.
The PSMA PET diagnostic market is projected to exceed US$3 billion by 2030, with potential growth beyond US$5 billion as indications expand. Clarity’s product offers a longer imaging window and improved sensitivity compared to current standards, which have struggled to meet sensitivity endpoints in pivotal trials. This positions 64Cu-SAR-bisPSMA as a potential best-in-class agent with broad commercial appeal.
Ongoing Registrational Trials and Next Steps
Clarity is progressing two pivotal Phase III trials: CLARIFY in high-risk prostate cancer patients prior to prostatectomy, and AMPLIFY in patients with biochemical recurrence. Both studies aim to validate the diagnostic accuracy and clinical utility of 64Cu-SAR-bisPSMA, with endpoints including sensitivity, specificity, and impact on management decisions.
Meanwhile, the SECuRE trial continues to enrol patients to confirm the safety and efficacy profile of 67Cu-SAR-bisPSMA therapy. The company’s experienced management team, including executives with deep expertise in radiopharmaceuticals and oncology, is steering these clinical programs alongside commercial partnerships and manufacturing agreements to support anticipated market entry.
Bottom Line?
Clarity’s SAR-bisPSMA candidates demonstrate compelling clinical differentiation, but regulatory approvals and reimbursement decisions will be critical to unlocking their commercial potential in a competitive prostate cancer imaging and therapy landscape.
Questions in the middle?
- Will next-day imaging with 64Cu-SAR-bisPSMA become a standard clinical practice or remain a niche option?
- How will Clarity navigate regulatory and reimbursement pathways in the US to capitalise on the large PSMA PET market?
- Can 67Cu-SAR-bisPSMA sustain durable responses in later-phase trials and expand beyond heavily pre-treated mCRPC?
